Theradaptive moves OsteoAdapt SP into pivotal FDA-backed trial: full analysis

Theradaptive has received FDA approval to move OsteoAdapt SP into a pivotal Phase 3 clinical trial, marking a key regulatory step for the company’s spinal fusion program. The pivotal OASIS study will test the investigational product as an alternative to autologous and allograft bone graft in single-level TLIF, ALIF, and LLIF procedures for degenerative disease of the lumbosacral spine. Theradaptive said the milestone positions the program for a future premarket approval submission if the data are positive. (prnewswire.com)

The latest decision builds on several earlier regulatory and development milestones. In December 2024, the FDA approved an expansion of Theradaptive’s Phase I/II IDE program, broadening OASIS beyond TLIF to also include ALIF and LLIF, and tripling the number of U.S. investigational sites, according to the company. CMS records also show the study’s IDE-linked entry under NCT06154005, with an approval date of October 11, 2024. Theradaptive has also previously disclosed Breakthrough Device designations for OsteoAdapt SP in spinal fusion indications, a program FDA says is intended to speed development and review of qualifying devices and device-led combination products. (prnewswire.com)

At the product level, OsteoAdapt SP is designed to pair AMP2, Theradaptive’s engineered variant of BMP-2, with a synthetic bone graft. The company’s argument is that modifying BMP-2 to bind tightly to a carrier could preserve bone-forming activity while reducing the off-target effects that have long complicated use of conventional rhBMP-2 in spine surgery. On its OASIS trial site, Theradaptive says participants are randomized 2:1 to receive OsteoAdapt SP or standard bone graft, with follow-up through 24 months. The company’s patient-facing materials list planned enrollment of up to 80 patients in the early-stage trial, underscoring that the pivotal program represents a meaningful escalation in the evidence package. (prnewswire.com)

Preclinical data have helped shape that narrative. A 2024 paper in Spine reported that OsteoAdapt SP produced faster and more robust bone formation than autologous iliac crest bone graft in an ovine lumbar interbody fusion model, with no evidence of systemic toxicity in the study. Theradaptive has pointed to those findings, alongside roughly 100 treated participants in earlier clinical experience and enrollment expansion into Australia and Israel, as support for advancing into the pivotal stage. Independent reporting from ORTHOWORLD largely echoed the company’s framing of the trial as a bid to improve both safety and efficacy in spinal fusion biologics. (pmc.ncbi.nlm.nih.gov)

Expert reaction outside company statements appears limited so far, which is common this early in a privately held company’s regulatory update. Still, the broader clinical context is clear: BMP-2 remains important in spine fusion, but published reviews have noted persistent concerns around dose, carrier selection, heterotopic bone formation, radiculitis, and other off-target effects depending on indication and surgical approach. That helps explain why a localized, carrier-bound BMP-like approach could attract attention from surgeons, investors, and strategic partners if pivotal data are strong. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this isn’t a companion-animal product launch, but it is a useful signal from the regenerative medicine pipeline. Orthobiologics that aim to localize growth-factor activity and reduce adverse effects are highly relevant to the broader musculoskeletal field, including translational research that often crosses between human and veterinary orthopedics. The bigger takeaway is that regulators and developers continue to back next-generation bone-healing platforms, especially those trying to improve on graft-harvest morbidity and the known limitations of legacy BMP strategies. (theradaptive.com)

What to watch: The next milestones are pivotal-study initiation, site activation, enrollment pace, and eventual disclosure of the trial’s design endpoints and timing. Because FDA’s Breakthrough Devices Program can support more frequent interaction and prioritized review, positive pivotal data could accelerate the path to a PMA filing, but the program still has to meet the agency’s usual safety and effectiveness standards. (fda.gov)